TB-500 is a synthetic peptide modeled after a region of thymosin beta-4 (Tβ4), widely discussed in research settings for its potential roles in tissue repair, angiogenesis, and inflammation modulation. This page is for research use context only and is not medical advice.
— 5 mg Vial —
Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
Typical daily range: 500–1000 mcg once daily (gradual titration recommended).
Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.
Storage: Lyophilized: store at −20 °C; reconstituted: refrigerate at 2–8 °C, do not freeze reconstituted solution.
Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Cycle Length: 8–12 weeks; optional extension to 16 weeks.
Goal: Support tissue repair, wound healing, and angiogenesis through the active thymosin beta-4 fragment mechanism.
Frequency: Inject once daily subcutaneously. Total weekly dose averages ~5 mg, consistent with research protocols.
| Phase | Dose | Syringe (U-100) |
|---|---|---|
| Weeks 1–2 | 500 mcg | 30 units (0.30 mL) |
| Weeks 3–4 | 600 mcg | 36 units (0.36 mL) |
| Weeks 5–8 | 750 mcg | 45 units (0.45 mL) |
| Weeks 9–12 | 1000 mcg | 60 units (0.60 mL) |
— 10 mg Vial —
Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
Typical daily range: 500–1000 mcg once daily (gradual titration recommended).
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
Storage: Lyophilized: store at −20 °C; reconstituted: refrigerate at 2–8 °C, do not freeze reconstituted solution.
Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Cycle Length: 8–12 weeks; optional extension to 16 weeks.
Goal: Support tissue repair, wound healing, and angiogenesis through the active thymosin beta-4 fragment mechanism.
Frequency: Inject once daily subcutaneously. Total weekly dose averages ~5 mg, consistent with research protocols.
| Phase | Dose | Syringe (U-100) |
|---|---|---|
| Weeks 1–2 | 500 mcg | 15 units (0.15 mL) |
| Weeks 3–4 | 600 mcg | 18 units (0.18 mL) |
| Weeks 5–8 | 750 mcg | 23 units (0.23 mL) |
| Weeks 9–12 | 1000 mcg | 30 units (0.30 mL) |
Thymosin beta-4 is a naturally occurring 43–amino acid peptide found in many tissues. It binds G-actin and is involved in cell migration and wound repair biology. “TB-500” is commonly marketed as a thymosin beta-4 fragment (varies by vendor), and research discussions often extrapolate from the larger Tβ4 literature.
- Soft tissue repair signals: cell migration, extracellular matrix remodeling (preclinical).
- Angiogenesis support: vascular growth signaling in wound models.
- Anti-inflammatory signaling: modulation of inflammatory pathways in certain injury contexts.
- Cardiac repair research: studied in myocardial injury models.
- Hair follicle biology: Tβ4 has been evaluated in hair growth/wound healing contexts.
Mechanistic work on thymosin beta-4 suggests effects related to actin sequestration, enhanced cell migration, and altered expression of repair-associated genes. In some models it has been linked to angiogenic signaling and changes in inflammatory mediators. Note: data are largely preclinical and context-dependent, and fragment peptides may not replicate full-length Tβ4 biology.
- Injection site irritation (if injected in research settings).
- Transient fatigue or headache (anecdotal reports).
- Unknown long-term risks due to limited controlled human data for TB-500 products.
- Pregnancy or breastfeeding (insufficient safety data).
- Active malignancy or history of cancer (angiogenesis/growth signaling is a theoretical concern).
- Use with anticoagulants/bleeding disorders: consult a clinician (general injection/hematoma risk).
In underground research practice, TB-500 is commonly administered subcutaneously (SubQ) for convenience, while intramuscular (IM) injection is sometimes chosen when targeting local tissue regions. There is no high-quality evidence demonstrating superior outcomes for SubQ vs IM in humans.
- BPC-157: often discussed alongside TB-500 for soft tissue repair research narratives.
- Collagen support (nutrition, vitamin C): commonly paired in injury-rehab discussions (not peptide-specific evidence).
- GH/IGF axis peptides: sometimes stacked in performance circles; increases complexity and unknowns.
- Thymosin beta-4 and wound repair biology. Ann N Y Acad Sci. 2007. PMID: 17413026
- Thymosin beta-4 promotes cardiac repair after myocardial infarction (preclinical). Nature. 2004. PMID: 15526016
- Thymosin beta-4 and corneal wound healing / inflammation modulation. Invest Ophthalmol Vis Sci. 2001. PMID: 11431452
- Tβ4 / actin-binding and cell migration relevance. J Cell Biol. 1990. PMID: 2403999
- Thymosin beta-4 in angiogenesis / vascular biology context. FASEB J. 2003. PMID: 12626435
- Thymosin beta-4 and hair follicle / skin repair-related research context. J Invest Dermatol. 2012. PMID: 22277948
If you want, I can add a compact “quick-dose math” table for a specific vial size you stock (2 mg, 5 mg, or 10 mg) and your preferred reconstitution volume.